Business Wire · ZURA · November 9, 2026

Zura Bio Provides Clinical Update on Phase 2 TibuSHIELD Study of Tibulizumab (ZB-106) in Hidradenitis Suppurativa

Get the app for more

Explore stock news, insights and company research.